Outcomes Data For Sanofi/Regeneron’s Praluent May Land In 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analyses from the events-driven trial of the PCSK9 inhibitor may be available next year, helping to pave the way for broader labeling.
You may also be interested in...
PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data
With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.